Jeff Yass’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-5,085
| Closed | -$55K | – | 13871 |
|
|
2023
Q4 | $68.6K | Buy |
+5,085
| New | +$82.4K | ﹤0.01% | 11557 |
|
|
2023
Q3 | – | Sell |
-1,706
| Closed | -$54.7K | – | 13504 |
|
|
2023
Q2 | $65.7K | Buy |
1,706
+623
| +58% | +$22K | ﹤0.01% | 11214 |
|
|
2023
Q1 | $30K | Buy |
1,083
+230
| +27% | +$7.8K | ﹤0.01% | 11908 |
|
|
2022
Q4 | $28.1K | Sell |
853
-1,053
| -55% | -$76.8K | ﹤0.01% | 11645 |
|
|
2022
Q3 | $231K | Sell |
1,906
-782
| -29% | -$141K | ﹤0.01% | 10481 |
|
|
2022
Q2 | $470K | Sell |
2,688
-1,133
| -30% | -$239K | ﹤0.01% | 8420 |
|
|
2022
Q1 | $1.11M | Sell |
3,821
-2,371
| -38% | -$900K | ﹤0.01% | 6858 |
|
|
2021
Q4 | $3.23M | Buy |
6,192
+3,057
| +98% | +$2.19M | ﹤0.01% | 4514 |
|
|
2021
Q3 | $1.19M | Buy |
3,135
+2,704
| +627% | +$1.16M | ﹤0.01% | 7091 |
|
|
2021
Q2 | $384K | Buy |
431
+357
| +482% | +$273K | ﹤0.01% | 10231 |
|
|
2021
Q1 | $88K | Buy |
+74
| New | +$102K | ﹤0.01% | 11906 |
|
Jeff Yass's BIOR Position: Q1 2024 in Review
Jeff Yass sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q1 2024, closing a stake of 5,085 shares — an estimated $55K sold.
Jeff Yass first reported a position in BIOR in Q1 2021 and held it in 11 quarters. The position peaked at $3.23M in Q4 2021. 27 funds tracked by Wall St. Rank hold BIOR as of Q1 2024.
- Jeff Yass reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Jeff Yass sold 5,085 Biora Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $55K.
- Jeff Yass first reported a position in Biora Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
- Jeff Yass's Biora Therapeutics, Inc. Common Stock position peaked at $3.23M in Q4 2021.
- 27 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.